Models of treatment with antipsychotics of the schizophrenic patients
- PMID: 16351603
- PMCID: PMC7202169
- DOI: 10.17305/bjbms.2005.3238
Models of treatment with antipsychotics of the schizophrenic patients
Abstract
The aim of this study were to determine which antipsychotic are currently in use, to establish which doses are administrated to patients, to find out is there a practice of proscribing simultaneously more then one antipsychotic drug, to determine whether antipsychotic are proscribed in divided doses, to establish whether there is, besides antipsychotics, treatment with other medicaments (co-administration), especially with antiparkinsonics. The research (study) is epidemiological-clinical prospective, descriptive and analytical and it was conducted at University hospitals in Sarajevo, Tuzla and Mostar. Criteria for inclusion, non-inclusion and exclusion from the study were precisely defined as a mean for formation of sample. Based on this hypothesis were established, zero and alterative. According to zero hypothesis in the treatment of schizophrenia at University hospitals in FBiH new antipsychotic drugs are in use, small doses are proscribed (up to 20 mg), not more then one antipsychotic drug is used simultaneously, antipsychotics are administrated once a day and alongside with antipsychotics other medicaments are not co-administrated, especially antiparkinsons. The results of our study are showing that majority of patients are treated with classical antipsychotics. Minority of patients is treated with atypical neuroleptics like olanzapine, which is proscribed only in Sarajevo. Use of risperidone and ziprasidone is registered also only in Sarajevo, but only small number of patients is treated with these drugs. Most frequent antipsychotics were promazine and haloperidol. The range between minimal and maximal daily dose of promazine was from 50 to 450 mg/daily, and for haloperidol from 1 to 75 mg/daily. Above-mentioned drugs were administrated in an average from two to three times a day. Alongside with antipsychotics, other drugs were used. Most frequent was the use of biperidine in oral and parenteral formulation, as well as nitrazepam and diazepam. The importance of this study is following: data are useful for the current mental health care reform in FBiH, results will point out place and position of FBiH in contemporary world trends in the treatment of schizophrenia, they will contribute to rational use of antipsychotic therapy, they will point out possible ways in reduction of side effects, often dangerous adverse effects of antipsychotics, and they will give contribution to faster rehabilitation of schizophrenics with the reduction of financial means for the treatment of patients with schizophrenia.
Figures
Similar articles
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
-
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.Turk Psikiyatri Derg. 2022 Summer;33(2):146-148. doi: 10.5080/u26315. Turk Psikiyatri Derg. 2022. PMID: 35730516 English, Turkish.
-
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.BMC Psychiatry. 2006 Feb 21;6:8. doi: 10.1186/1471-244X-6-8. BMC Psychiatry. 2006. PMID: 16504026 Free PMC article. Clinical Trial.
-
An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Hum Psychopharmacol. 2011. PMID: 23055416 Review.
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
References
-
- Loga S. Loga S, editor. Treatment psychiatric disorders, in Clinical psychiatry. Faculty of Medicine Sarajevo and Tuzla. :299–314.
-
- Loga S. Loga S, editor. Treatment psychiatric disorders, in Clinical psychiatry. Faculty of Medicine Sarajevo and Tuzla. :299–314.
-
- Baldessarini R. J, Kando J.C, Centorrino F. Hospitaluse of an-tipsychotic agents in 1989 and 1993 stable dosing with decreased length of stay. Am J Psychiatry. 1995;152(7):1038–1044. - PubMed
-
- Rosenheck R, Cramer J, Allan E, et al. Cost effectiveness of clozap-ine in patients with high and low levels of hospital use. Arch. of Gen. Psychiatry. 1999;56:565–572. - PubMed
-
- Van der Zwaag C, McvGee M, McEvoy J.P, Freuden-Reich O, Wilson W. H, Copper T.B. Response of patients with treatment-refractory schizophrenia to clozapine within three serum ranges. Am J Psychiatry. 1996;153:1579–1584. - PubMed